Disc Medicine Inc.
$ 67.99
-0.13%
12 Jun - close price
- Market Cap 2,597,156,000 USD
- Current Price $ 67.99
- High / Low $ 70.18 / 67.64
- Stock P/E N/A
- Book Value 18.03
- EPS -6.64
- Next Earning Report 2026-08-06
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.23 %
- ROE -0.36 %
- 52 Week High 99.50
- 52 Week Low 40.00
About
Disc Medicine, Inc., a clinical-stage biotechnology company, engages in discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases. The company is headquartered in Watertown, Massachusetts.
Analyst Target Price
$101.09
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-05 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-07 | 2025-02-27 | 2024-11-12 | 2024-08-08 | 2024-05-09 | 2024-03-21 | 2023-11-09 | 2023-08-11 |
| Reported EPS | -1.65 | -1.64 | -1.77 | -1.58 | -1.02 | -0.98 | -0.8885 | -1.03 | -1.09 | -0.9 | -0.58 | -0.74 |
| Estimated EPS | -1.78 | -1.75 | -1.48 | -1.12 | -1.0738 | -1.1036 | -1.05 | -1.11 | -1 | -0.78 | -0.8 | -0.86 |
| Surprise | 0.13 | 0.11 | -0.29 | -0.46 | 0.0538 | 0.1236 | 0.1615 | 0.08 | -0.09 | -0.12 | 0.22 | 0.12 |
| Surprise Percentage | 7.3034% | 6.2857% | -19.5946% | -41.0714% | 5.0102% | 11.1997% | 15.381% | 7.2072% | -9% | -15.3846% | 27.5% | 13.9535% |
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-06 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -1.59 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IRON
2026-06-14 11:40:20
NEXTBio Capital Management LP has initiated a new position in Disc Medicine, Inc. (NASDAQ:IRON), acquiring 42,778 shares valued at approximately $3.4 million, which constitutes about 2% of its portfolio. This move comes as institutional investors like Vanguard, JPMorgan, and Goldman Sachs have also increased their holdings, despite recent insider share sales. Analysts generally maintain a "Moderate Buy" rating with an average target price of $105.30 for the clinical-stage biotechnology company.
2026-06-12 18:09:54
Disc Medicine (NASDAQ:IRON) presented updated clinical trial data for two investigational treatments, DISC-0974 and bitopertin, for blood disorders at the European Hematology Association Annual Meeting. The company's stock is currently trading at $68.08, down 26% over the past six months, though analysts still maintain a strong buy consensus with significant upside potential. Disc Medicine plans further discussions with the FDA for DISC-0974 by year-end and expects Phase 3 trial readouts for bitopertin in Q4.
2026-06-12 17:09:19
Disc Medicine (NASDAQ:IRON) presented updated clinical trial data for two investigational treatments, DISC-0974 and bitopertin, at the European Hematology Association Annual Meeting. The company plans End of Phase 2 discussions with the FDA for DISC-0974 by year-end and expects Phase 3 bitopertin readout in Q4, potentially supporting traditional approval. Initial data from the RESTORE-PV Phase 2 trial of DISC-3405 is anticipated in Q4 2026, with Stifel reiterating a Buy rating on the company.
2026-06-12 14:12:00
Disc Medicine (NASDAQ:IRON) presented positive clinical data for its hematology pipeline at the 2026 European Hematology Association (EHA) Annual Meeting. The company highlighted strong efficacy for DISC-0974 in myelofibrosis-associated anemia, showing significant hemoglobin increases and transfusion independence, and for bitopertin in erythropoietic protoporphyria (EPP), demonstrating sustained reduction in toxic PPIX levels and improved light tolerance. These results establish key catalyst events for Disc Medicine in the second half of 2026.
2026-06-12 12:39:57
Disc Medicine (NASDAQ: IRON) announced positive updated clinical data for its therapies at the 2026 European Hematology Association (EHA) Annual Meeting. The Phase 2 RALLY-MF trial of DISC-0974 for myelofibrosis anemia showed meaningful and durable anemia responses across patient subgroups. Additionally, the HELIOS extension data for bitopertin in EPP demonstrated sustained reductions in protoporphyrin IX (PPIX) and improved light tolerance, along with a favorable long-term safety profile.
2026-06-12 12:39:57
Disc Medicine announced positive clinical updates for its multiple programs at the 2026 EHA Annual Meeting. Data from the RALLY-MF trial for DISC-0974 in myelofibrosis and anemia showed durable anemia responses across patient subgroups, while updated HELIOS data for bitopertin in erythropoietic protoporphyria demonstrated sustained reductions in PPIX and improved light tolerance. The company anticipates further data releases and significant milestones in its pipeline, including a Phase 3 readout for bitopertin and initial data for DISC-3405 later this year.
